GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (FRA:8EM) » Definitions » GF Value

Editas Medicine (FRA:8EM) GF Value : €13.37 (As of Dec. 13, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Editas Medicine GF Value?

As of today (2024-12-13), Editas Medicine's share price is €1.827. Editas Medicine's GF Value is €13.37. Therefore, Editas Medicine's Price-to-GF-Value for today is 0.14. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Editas Medicine is Possible Value Trap, Think Twice.

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

  1. Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
  2. GuruFocus adjustment factor based on the company’s past returns and growth.
  3. Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

Editas Medicine  (FRA:8EM) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Editas Medicine's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=1.827/13.37
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Editas Medicine GF Value Related Terms

Thank you for viewing the detailed overview of Editas Medicine's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Editas Medicine Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (FRA:8EM) » Definitions » GF Value
Comparable Companies
HLVX OABI TRDA PHAT TVTX ETNB ARCT SVRA WVE ELVN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
EDIT:USA 0IFK:UK
Address
11 Hurley Street, Cambridge, MA, USA, 02141
Website
https://www.editasmedicine.com
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Editas Medicine Headlines

No Headlines